Smartleaf Asset Management
CSTL icon

Smartleaf Asset Management’s Castle Biosciences CSTL Stock Holding History

Smartleaf Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-8
Closed -$213 – 3672
2026
Q2 		$213 Hold
8
– – ﹤0.01% 3298
2026
Q1 		$207 Buy
+8
New +$262 ﹤0.01% 3334

Other funds holding CSTL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Smartleaf Asset Management's CSTL Position: Q3 2026 in Review

Smartleaf Asset Management sold out of Castle Biosciences (CSTL) in Q3 2026, closing a stake of 8 shares — an estimated $213 sold.

Smartleaf Asset Management first reported a position in CSTL in Q1 2026 and held it in 2 quarters. The position peaked at $213 in Q2 2026. 94 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Smartleaf Asset Management reported no remaining Castle Biosciences position as of Q3 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 8 Castle Biosciences shares in Q3 2026, an estimated $213.
  • Smartleaf Asset Management first reported a position in Castle Biosciences in Q1 2026 and held it in 2 quarters.
  • Smartleaf Asset Management's Castle Biosciences position peaked at $213 in Q2 2026.
  • 94 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.